Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 9:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 2,486 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumor, NSCLC, CRC
Interventions
JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor)
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Conditions
Advanced Solid Tumor, Ovarian Cancer
Interventions
Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg, Niraparib 100 mg, Niraparib 200 mg, Niraparib 300 mg, Niraparib at RP2D, Neratinib at RP2D
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Neoplasm Metastasis
Interventions
MK-6837, Pembrolizumab, Rescue Medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Morristown, New Jersey • Portland, Oregon • San Antonio, Texas
Conditions
Advanced Cancer, Metastatic Cancer
Interventions
Mocaciclib (Q901), KEYTRUDA® (pembrolizumab), Fulvestrant
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Conditions
Cancer, Cancer (Solid Tumors)
Interventions
JMT108
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Huntersville, North Carolina • Dallas, Texas • Fairfax, Virginia
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid Tumors
Interventions
MC001
Biological
Lead sponsor
Medicovestor, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Syracuse, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more
Conditions
Advanced Solid Tumors
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • San Antonio, Texas • Madison, Wisconsin
Conditions
Glioma
Interventions
AG881
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Conditions
Cancer
Interventions
eFT508
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor, Marginal Zone Lymphoma
Interventions
Tazemetostat, Fluconazole, Omeprazole, Repaglinide
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • New York, New York
Conditions
Solid Tumors
Interventions
GO-203-2c
Drug
Lead sponsor
Genus Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 1 more
Conditions
Advanced Solid Tumors, HER2-positive Breast Cancer
Interventions
ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Cerritos, California • San Francisco, California + 5 more
Conditions
Solid Tumors
Interventions
NKP-1339
Drug
Lead sponsor
Niiki Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • Nashville, Tennessee
Conditions
Advanced Solid Tumors
Interventions
CP-868,596, Docetaxel, AG-013736
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Solid Tumors
Interventions
Compound AC220
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • San Antonio, Texas
Conditions
Tumors
Interventions
Dasatinib + Ketoconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Santa Monica, California • Tampa, Florida • Nashville, Tennessee + 1 more
Conditions
Advanced Solid Tumor
Interventions
ATRN-119
Drug
Lead sponsor
Aprea Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Cleveland, Ohio • Philadelphia, Pennsylvania + 4 more
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
CDK Inhibitor AT7519, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Conditions
Solid Tumor, Adult
Interventions
BGB-24714, Paclitaxel, Carboplatin, Docetaxel
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Gilbert, Arizona • Sarasota, Florida • St. Petersburg, Florida + 12 more
Conditions
Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer
Interventions
124I-NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Neoplasms
Interventions
AB0024
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Conditions
Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
Interventions
PF-08046031
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 1 more
Conditions
Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
Interventions
TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel
Drug
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more
Conditions
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
MRG007, MRG007 and Bevacizumab
Drug
Lead sponsor
ArriVent BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more